by Jon C. Martin, DO, and Danielle Gainer, MD Dr. Martin is with Wright Patterson Medical Center in Wright-Patterson Air Force Base, Ohio. Dr. Gainer is with Wright State University
Innov Clin Neurosci. 2016;13(7–8):13–14. Dear Editor: Substance use disorders frequently coexist with and complicate the treatment of mood and anxiety disorders. Gabapentin is one of the most commonly prescribed off-label
by Atmaram Yarlagadda, MD; Ganesh Acharya, MD, PhD, FRCOG; Jayaprada Kasaraneni, MBBS; Christiane S. Hampe, PhD; and Anita H. Clayton, MD Dr. Yarlagadda is Chief of Psychiatry, Behavioral Health Services,
by David R. Spiegel, MD, and Kathryn Webb, MD Drs. Spiegel and Webb are from Eastern Virginia Medical School, Department of Psychiatry and Behavioral Sciences in Norfolk, Virginia. Innov Clin
by Peter Dussias; Amir H. Kalali, MD; and Roland M. Staud, MD Mr. Dussias is Executive Director, Strategic Analytics Commercial Solutions, Quintiles, Parsippany, New Jersey; Dr. Kalali is Vice President,
by Elisa Cascade; Amir H. Kalali, MD; and Richard H. Weisler, MD Ms. Cascade is Vice President, Quintiles Inc./iGuard, Falls Church, Virginia; Dr. Kalali is Vice President, Global Therapeutic Group
